NeoGenomics, Inc. (NEO): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el paisaje en rápida evolución de la oncología de precisión, Neogenomics, Inc. (NEO) emerge como una fuerza transformadora, revolucionando el diagnóstico del cáncer a través de tecnologías genómicas de vanguardia. Al integrar a la perfección, las pruebas moleculares avanzadas, las asociaciones de investigación colaborativa y las soluciones de diagnóstico personalizadas, la compañía está redefiniendo cómo los médicos e investigadores abordan la detección, comprensión y tratamiento del cáncer. Este lienzo de modelo de negocio integral revela el plan estratégico que impulsa la neogenómica de un servicio de laboratorio especializado a un jugador fundamental en el ecosistema genómico de la salud, que ofrece ideas sin precedentes que podrían cambiar la trayectoria de la gestión del cáncer.

Neogenomics, Inc. (NEO) - Modelo de negocios: asociaciones clave

Centros de investigación de oncología e instituciones académicas

Neogenomics ha establecido asociaciones con las siguientes instituciones de investigación:

Institución	Enfoque de colaboración
Centro de cáncer de MD Anderson	Investigación de oncología de precisión
Universidad de Stanford	Desarrollo de pruebas genómicas
Clínica de mayonesa	Análisis de biomarcadores de ensayos clínicos

Compañías farmacéuticas y de biotecnología

Las asociaciones farmacéuticas clave incluyen:

• Merck & Co.
• Bristol Myers Squibb
• Astrazeneca
• Pfizer

Proveedores de atención médica y hospitales

Red de atención médica	Detalles de la asociación	Volumen de prueba anual
Hackensack Meridian Health	Pruebas de oncología integrales	45,000 pruebas/año
Memorial Sloan Kettering	Perfil molecular avanzado	38,000 pruebas/año

Proveedores de equipos y tecnología de laboratorio

Socios de tecnología primaria:

• Illumina (plataformas de secuenciación de próxima generación)
• Thermo Fisher Scientific
• Roche Diagnostics

Redes de ensayos clínicos y organizaciones de investigación

Organización	Tipo de asociación	Pruebas activas
Red de investigación sobre el cáncer SWOG	Ensayos clínicos de oncología	27 pruebas activas
Grupo de investigación del cáncer de EcoG-ACRIN	Estudios de perfiles moleculares	19 ensayos activos

Ecosistema de asociación total: 42 colaboraciones institucionales activas a partir de 2024

Neogenomics, Inc. (NEO) - Modelo de negocio: actividades clave

Pruebas genéticas y moleculares para diagnósticos de cáncer

Neogenomics realizó 585,000 pruebas moleculares en 2022. La compañía procesó aproximadamente 1,2 millones de pruebas en su red de laboratorios. Los ingresos por pruebas genéticas alcanzaron los $ 499.2 millones en 2022.

Categoría de prueba	Volumen (2022)	Impacto de ingresos
Pruebas de oncología de precisión	385,000	$ 327.4 millones
Pruebas de diagnóstico molecular	200,000	$ 171.8 millones

Desarrollo de tecnologías de prueba genómica avanzada

Neogenomics invirtió $ 75.4 millones en investigación y desarrollo en 2022. La Compañía mantiene 14 laboratorios certificados por CLIA y acreditados por CAP especializados en tecnologías genómicas avanzadas.

• Plataformas de secuenciación de próxima generación (NGS)
• Tecnologías integrales de perfiles genómicos
• Capacidades de prueba de biopsia líquida

Proporcionar soluciones de medicina de precisión

La Compañía procesó 165,000 pruebas de medicina de precisión en 2022, generando $ 213.6 millones en ingresos de pruebas de oncología especializada.

Servicio de medicina de precisión	Volumen de prueba	Ganancia
Guía de terapia dirigida	95,000	$ 122.7 millones
Detección de biomarcadores	70,000	$ 90.9 millones

Realización de ensayos clínicos e investigación

Neogenomics participó en 87 ensayos clínicos en 2022, con colaboraciones de investigación por un total de $ 42.3 millones en fondos externos.

• Investigación clínica centrada en la oncología
• Asociaciones de la compañía farmacéutica
• Colaboraciones de la institución académica

Ofreciendo servicios de laboratorio y consultoría

Los servicios de laboratorio generaron $ 612.5 millones en ingresos totales para 2022. La compañía mantiene una red de 14 instalaciones de laboratorio en los Estados Unidos.

Categoría de servicio	Ganancia	Base de clientes
Servicios de laboratorio clínico	$ 475.3 millones	Más de 2,300 proveedores de atención médica
Consultoría farmacéutica	$ 137.2 millones	180+ compañías farmacéuticas

Neogenomics, Inc. (NEO) - Modelo de negocios: recursos clave

Tecnologías avanzadas de prueba genética

Neogenomics opera con tecnologías avanzadas que incluyen:

• Plataformas de secuenciación de próxima generación (NGS)
• Sistemas de diagnóstico molecular
• Equipo de prueba citogenética

Categoría de tecnología	Inversión en equipos	Costo de mantenimiento anual
Plataformas NGS	$ 12.3 millones	$ 1.7 millones
Sistemas de diagnóstico molecular	$ 8.6 millones	$ 1.2 millones
Equipo de prueba citogenética	$ 5.4 millones	$850,000

Infraestructura de laboratorio especializada

Neogenomics mantiene 7 laboratorios certificados por CLIA En los Estados Unidos con un espacio total de laboratorio de aproximadamente 120,000 pies cuadrados.

Profesionales científicos y médicos altamente calificados

Composición de la fuerza laboral a partir de 2024:

• Total de empleados: 1.236
• Científicos a nivel de doctorado: 187
• Patólogos certificados por la junta: 64
• Científicos de laboratorio clínico: 412

Bases de datos y plataformas de investigación genómicas patentadas

Tipo de base de datos	Total de registros	Tasa de actualización anual
Base de datos genómica del cáncer	528,000 registros de pacientes	17.3%
Repositorio de biomarcadores de oncología	276,000 perfiles moleculares	14.6%

Patentes de propiedad y investigación intelectual

Cartera de patentes a partir de 2024:

• Patentes activas totales: 37
• Patentes del método de prueba genómica: 22
• Patentes de tecnología de diagnóstico: 15

Neogenomics, Inc. (NEO) - Modelo de negocio: propuestas de valor

Prueba de oncología de precisión integral

Neogenomics ofrece más de 3,400 pruebas moleculares y de patología con un enfoque en el diagnóstico del cáncer. La compañía procesó 667,000 casos en 2022, generando $ 687.4 millones en ingresos totales.

Categoría de prueba	Número de pruebas	Utilidad clínica
Perfil molecular	1.850 pruebas únicas	Ideas genómicas específicas del cáncer
Servicios de patología	1.550 pruebas especializadas	Caracterización detallada del cáncer

Soluciones de diagnóstico de cáncer personalizadas

Neogenomics proporciona Pruebas genéticas personalizadas con una tasa de precisión del 98.7% en múltiples tipos de cáncer.

• Perfil genómico integral
• Análisis de mutación dirigida
• Identificación de biomarcador

Detección temprana y recomendaciones de tratamiento dirigido

Las plataformas de prueba de la compañía respaldan la detección temprana del cáncer con una sensibilidad del 92.4% en los principales tipos de cáncer.

Tipo de cáncer	Sensibilidad a la detección	Terapias dirigidas
Cáncer de pulmón	94.2%	25 terapias dirigidas
Cáncer de mama	93.7%	18 terapias dirigidas

Ideas genómicas avanzadas para los médicos

Neogenomics sirve a más de 3.800 socios clínicos con servicios integrales de informes y consultas.

• Interpretación genómica en tiempo real
• Coincidencia de ensayos clínicos
• Consulta de estrategia de tratamiento

Servicios innovadores de perfiles moleculares

La compañía invirtió $ 82.3 millones en I + D durante 2022, centrándose en tecnologías avanzadas de perfiles moleculares.

Tecnología	Inversión de I + D	Capacidades únicas
Secuenciación de próxima generación	$ 42.1 millones	Paisaje genómico integral
Tecnologías de biopsia líquida	$ 40.2 millones	Detección de cáncer no invasivo

Neogenomics, Inc. (NEO) - Modelo de negocios: relaciones con los clientes

Ventas directas y gestión de cuentas

Neogenomics mantiene un equipo de ventas dedicado de 87 representantes de ventas directas a partir de 2023. El enfoque de ventas directas de la compañía se dirige a los laboratorios de oncología, hospitales y compañías farmacéuticas.

Segmento de clientes	Número de cuentas	Contribución anual de ingresos
Laboratorios de oncología	425	$ 187.3 millones
Hospitales	312	$ 142.6 millones
Compañías farmacéuticas	156	$ 98.7 millones

Plataformas de atención al cliente en línea

Neogenomics ofrece apoyo integral en línea a través de:

• Portal de clientes digitales 24/7
• Sistema de seguimiento de resultados de prueba en tiempo real
• Plataforma segura de gestión de documentos

Canal de soporte	Tiempo de respuesta promedio	Tasa de satisfacción del cliente
Portal en línea	2.3 horas	92%
Soporte por correo electrónico	4.1 horas	87%
Soporte telefónico	15 minutos	95%

Asociaciones de investigación colaborativa

La neogenómica participa en colaboraciones de investigación estratégica con 43 instituciones académicas y 28 organizaciones de investigación farmacéutica en 2023.

Tipo de asociación	Número de asociaciones activas	Inversión de investigación anual
Instituciones académicas	43	$ 12.5 millones
Organizaciones de investigación farmacéutica	28	$ 18.3 millones

Actualizaciones continuas de tecnología y servicio

Neogenomics invierte $ 37.6 millones anuales en investigación y desarrollo, con 62 proyectos de mejora de tecnología en curso en 2023.

Seminarios web educativos y conferencias científicas

La compañía organiza y participa en múltiples eventos científicos anualmente:

• 12 seminarios web internos
• 24 Presentaciones de conferencias externas
• 8 simposios científicos patrocinados

Tipo de evento	Número de eventos	Alcance de participante estimado
Seminarios web internos	12	3.500 participantes
Presentaciones de conferencias externas	24	7,200 participantes
Simposios científicos patrocinados	8	2.100 participantes

Neogenomics, Inc. (NEO) - Modelo de negocios: canales

Equipo de ventas directas

El equipo de ventas directas de Neogenomics consta de 154 representantes de ventas a partir del cuarto trimestre de 2023. El equipo genera aproximadamente $ 481.2 millones en ingresos anuales a través de interacciones directas del cliente.

Segmento del equipo de ventas	Número de representantes	Mercado objetivo
Especialistas en oncología	87	Clínicas de oncología
Especialistas en biofarma	42	Compañías farmacéuticas
Especialistas en investigación académica	25	Instituciones de investigación

Plataformas digitales en línea

Neogenomics opera múltiples canales digitales que generan el 22.3% de los ingresos totales en 2023, con un ingreso estimado de la plataforma en línea de $ 103.5 millones.

• Sistema de pedidos basado en la web
• Plataforma de informes de resultados digitales
• Sistema integrado de gestión de información de laboratorio

Conferencias médicas y ferias comerciales

En 2023, Neogenomics participó en 37 conferencias médicas internacionales, con una inversión estimada de redes y generación de leads de $ 2.4 millones.

Tipo de conferencia	Número de conferencias	Alcance estimado
Conferencias oncológicas	22	15,000 profesionales
Eventos de medicina de precisión	9	7.500 profesionales
Simposios de biofarma	6	5,000 profesionales

Redes de referencia profesionales de atención médica

Neogenomics mantiene las relaciones con 6.782 profesionales de la salud en 1,243 instituciones médicas, generando ingresos basados ​​en referencias de aproximadamente $ 76.9 millones en 2023.

Servicios de telemedicina y consulta digital

Los servicios de consulta digital representan el 8.6% de los ingresos totales, con $ 40.2 millones generados a través de plataformas de consulta de asesoramiento genético y pruebas moleculares en 2023.

• Sesiones de asesoramiento genético virtual
• Interpretación de pruebas moleculares remotas
• Consultas de patología digital

Neogenomics, Inc. (NEO) - Modelo de negocios: segmentos de clientes

Oncólogos y centros de tratamiento del cáncer

Neogenomics atiende aproximadamente 3.000 prácticas de oncología y centros de tratamiento del cáncer en los Estados Unidos.

Tipo de cliente	Número de clientes	Volumen de prueba anual
Prácticas oncológicas	2,500	Más de 450,000 pruebas anualmente
Centros de tratamiento del cáncer	500	Aproximadamente 250,000 pruebas anualmente

Organizaciones de investigación farmacéutica

Neogenomics apoya más de 100 organizaciones de investigación farmacéutica con servicios especializados de pruebas genómicas.

• Las 20 principales compañías farmacéuticas como clientes
• Apoya aproximadamente 75 ensayos clínicos anualmente
• Volumen de pruebas genómicas para la investigación: 150,000 muestras por año

Patrocinadores de ensayos clínicos

La compañía colabora con aproximadamente 250 patrocinadores de ensayos clínicos en múltiples áreas terapéuticas.

Tipo de prueba	Número de patrocinadores	Contratos anuales promedio
Pruebas de oncología	175	$ 45 millones en investigación por contrato
Otras áreas terapéuticas	75	$ 15 millones en investigación por contrato

Pacientes individuales que buscan pruebas genéticas

La neogenómica procesa aproximadamente 250,000 pruebas genéticas de pacientes individuales anualmente.

• Pruebas genéticas del cáncer: 180,000 pacientes
• Detección de cáncer hereditario: 70,000 pacientes
• Precio de prueba promedio: $ 1,200 - $ 3,500

Proveedores de seguro de salud

Neogenomics tiene contratos con el 85% de los principales proveedores de seguros de salud en los Estados Unidos.

Categoría de proveedor de seguros	Número de contratos	Volumen de reembolso anual
Aseguradoras nacionales	12	$ 280 millones
Aseguradoras regionales	45	$ 120 millones

Neogenomics, Inc. (NEO) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Neogenomics reportó gastos de I + D de $ 96.3 millones, lo que representa el 21.4% de los ingresos totales.

Inversiones de equipos e tecnología de laboratorio

Categoría de equipo	Monto de inversión (2023)
Plataformas de secuenciación de próxima generación	$ 12.5 millones
Instrumentos de diagnóstico molecular	$ 8.7 millones
Sistemas de análisis computacional	$ 6.3 millones

Personal de personal y personal científico especializado

Los gastos totales de personal para 2023 fueron de $ 218.6 millones, con un salario promedio para el personal científico que oscila entre $ 85,000 y $ 145,000 anuales.

• Patólogos moleculares: salario promedio de $ 127,500
• Científicos de investigación: salario promedio de $ 98,000
• Tecnólogos genéticos: salario promedio de $ 72,000

Ensayo clínico e financiación de la investigación

La financiación de la investigación clínica para 2023 totalizaron $ 42.1 millones, asignados a través de múltiples iniciativas de investigación de oncología y medicina de precisión.

Infraestructura de marketing y ventas

Categoría de gastos de marketing	Gasto (2023)
Marketing digital	$ 3.7 millones
Compensación del equipo de ventas	$ 22.4 millones
Participación de la conferencia y eventos	$ 1.9 millones

Costos operativos totales para 2023: $ 393.4 millones

Neogenomics, Inc. (NEO) - Modelo de negocios: flujos de ingresos

Tarifas de servicio de prueba de diagnóstico

Neogenomics reportó ingresos totales de $ 532.8 millones para el año fiscal 2022. Los servicios de pruebas de diagnóstico representaron la mayoría de estos ingresos.

Categoría de servicio	Ingresos (2022)	Porcentaje de ingresos totales
Prueba de diagnóstico de oncología	$ 412.3 millones	77.4%
Segmento de servicios farmacéuticos	$ 120.5 millones	22.6%

Contratos de soporte de ensayos clínicos

La neogenómica generó $ 129.1 millones a partir de servicios farmacéuticos y apoyo de ensayos clínicos en 2022.

• Valor promedio del contrato para pruebas genómicas de ensayos clínicos: $ 250,000 a $ 1.5 millones
• Número de contratos de ensayo clínico farmacéutico activo: 87

Colaboraciones de investigación farmacéutica

Las colaboraciones de investigación farmacéutica contribuyeron con $ 85.6 millones a los ingresos de la compañía en 2022.

Tipo de colaboración	Contribución de ingresos	Número de asociaciones activas
Colaboraciones de investigación oncológica	$ 62.3 millones	23
Colaboraciones de medicina de precisión	$ 23.3 millones	12

Servicios de consulta de medicina de precisión

Los servicios de consulta de medicina de precisión generaron $ 37.4 millones en ingresos para 2022.

• Tarifa de servicio de consulta promedio: $ 5,000 a $ 50,000
• Número total de clientes de consulta: 742

Ventas de kit de pruebas genéticas

Las ventas del kit de pruebas genéticas alcanzaron los $ 18.2 millones en 2022.

Tipo de kit	Volumen de ventas	Precio promedio del kit
Oncología kits de prueba genética	24,600 unidades	$650
Kits integrales de detección genética	11,300 unidades	$350

NeoGenomics, Inc. (NEO) - Canvas Business Model: Value Propositions

You're looking at what NeoGenomics, Inc. offers to its customers-the core reasons why oncologists, hospital systems, and biopharma partners choose them over the competition. It's all about breadth, speed, and actionable data in the complex world of cancer diagnostics.

The first big value is offering comprehensive oncology testing across the entire cancer continuum. NeoGenomics provides one of the most complete oncology-focused testing menus available, covering the full spectrum of cancer care needs. This breadth is anchored by a menu featuring over 500 oncology-focused tests.

Next, you see the push for innovative diagnostic and predictive testing for precision medicine. This isn't just running tests; it's about delivering deep insights for targeted therapy. For instance, their Comprehensive Genomic Profiling (CGP) panels identified actionable alterations in 67% of tumors tested, which is more than double the 33% found using a standard 50-gene targeted NGS panel. The PanTracer LBx liquid biopsy test, for example, analyzes a total of 514 genes.

Speed is a major differentiator in oncology, and NeoGenomics delivers with rapid turnaround times. Specifically, the NEO PanTracer LBx liquid biopsy test is designed to offer a seven-day turnaround time (TAT). For their tissue-based tests, the TAT is 8-10 days for PanTracer Tissue and PanTracer Tissue + HRD.

The company helps simplify operational workflows for institutions by consolidating send-out testing. By offering a holistic genomic picture through their PanTracer portfolio, they provide a frictionless, single-source workflow. This consolidation reduces the complexity for institutions managing multiple vendors for different types of testing.

The focus on advanced testing is clearly paying off in the financials, particularly in high-growth NGS testing. In the third quarter of 2025, Next-Generation Sequencing (NGS) revenue grew 24% year-over-year. This high-value segment now accounts for nearly one-third (or 33%) of their total clinical revenue. This growth in high-value testing helped drive the Average Revenue per Clinical Test (AUP) up to $476 in Q3 2025.

Here's a quick look at how their key portfolio elements stack up:

Value Component	Metric/Feature	Associated Number
Comprehensive Coverage	Total Genes Analyzed (PanTracer Portfolio)	Over 500
Precision Medicine Impact	Actionable Alterations Found (CGP vs. 50-gene panel)	67% vs. 33%
Speed of Results	PanTracer LBx Turnaround Time (TAT)	7 days
Growth Engine	NGS Revenue Growth (Q3 2025 YoY)	24%
Clinical Volume	Total Clinical Test Volume (Q3 2025)	361,000 tests

The value proposition is further supported by operational performance metrics from Q3 2025:

• Total Consolidated Revenue reached $188 million.
• Clinical Revenue grew 18% year-over-year.
• Clinical Test Volumes increased 15% year-over-year.
• The company is projecting full-year 2025 revenue between $720 million and $726 million.

They are delivering these results while focusing on integrating acquisitions, like Pathline, which was completed during the third quarter, including the validation of critical TAT-sensitive assays.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Customer Relationships

You're looking at how NeoGenomics, Inc. connects with the oncologists, pathologists, and hospital systems that rely on their specialized cancer testing. It's about making complex diagnostics accessible and actionable for the people treating patients every day. The company's strategy, as CEO Tony Zook noted entering 2025, centers on winning on customer experience while capitalizing on its commercial organization.

The structure for direct engagement relies heavily on a dedicated commercial sales team. NeoGenomics, Inc. has been actively optimizing and expanding this commercial organization throughout 2025. This team includes Oncology Sales Specialists focused on the community oncology segment, a group they expanded in 2024 to increase coverage as new products launched in 2025. While the exact current size of the dedicated sales force isn't public, the company had 2,200 total employees as of September 30, 2025, indicating the scale of the support structure behind these relationships. The acceleration point for contributions from this sales force was anticipated in the second half of 2025.

Consultative services from expert pathologists are a key differentiator, supporting the rapport NeoGenomics, Inc. has established with community pathologists and oncologists. This expert interaction helps translate complex genomic data into clinically actionable reports. The focus on high-value tests, like Next-Generation Sequencing (NGS), which grew 24% year-over-year in Q3 2025, suggests these consultative touchpoints are crucial for adoption.

The patient-centric strategy is designed to directly improve patient care, which is the ultimate measure of customer success. The company delivered a record number of results to patients in the first quarter of 2025. Furthermore, the long-range goal is to serve more than 1 million patients annually by 2028, showing a commitment to scaling this patient impact. This focus is reflected in the clinical volume growth, which increased 15% year-over-year in the third quarter of 2025.

To make doing business easier-a direct driver for customer retention-NeoGenomics, Inc. has heavily invested in its digital ecosystem. This includes direct user interfaces for ordering and accessing results. As of the end of 2024, the company had already implemented over 300 direct user interfaces with customers. This digital push is part of a broader strategy to transform the digital ecosystem, including migrating to a single Laboratory Information Management System (LIMS).

Here's a quick look at some of the key operational metrics that reflect the volume and value flowing through these customer relationships in 2025:

Metric	Period/Date	Value
Total Employees	September 30, 2025	2,200
Direct User Interfaces Implemented (Cumulative)	End of 2024 (Latest Figure)	Over 300
Average Revenue Per Clinical Test	Q3 2025	$476
Clinical Test Volume Growth (YoY)	Q3 2025	15%
NGS Revenue Growth (YoY)	Q3 2025	24%

The company's commitment to customer experience is supported by tangible results in test value and volume, even as they manage headwinds in non-clinical revenue.

• Focus on community oncology segment expansion.
• Goal to achieve 12-13% annual revenue growth for fiscal year 2025.
• NGS now accounts for nearly one-third of clinical revenue as of Q3 2025.
• Adjusted Gross Profit Margin was 47% in Q1 2025.

Finance: draft 13-week cash view by Friday.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Channels

Direct sales force to oncologists, pathologists, and hospitals

NeoGenomics, Inc. capitalizes on a commercial organization focused on the community setting, where approximately 80% of cancer care is delivered. The clinical services sales team is structured across nine regions in the United States. The company noted in its Q2 2025 update that it was 'continuing to grow our sales team.' For pharmaceutical development services, a dedicated team of business development specialists supports sponsors with testing needs for research and development projects, including Phase I, II, and III studies. Sales representatives manage their territories using a custom Customer Relationship Management System (CRM), which integrates key customer care functionality from the Laboratory Information Management System (LIMS) in real time.

Network of full-service, accredited laboratories for sample processing

NeoGenomics, Inc. maintains a network of laboratories across the US that are CAP-accredited and CLIA-certified for full-service sample processing and analysis. This network expanded with the completion of the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory in New Jersey, on April 4, 2025. Internationally, the company operates a CAP-accredited full-service, sample-processing laboratory located in Cambridge, United Kingdom. As of September 30, 2025, NeoGenomics (Fort Myers) had a total employee count of 2,200. The company has a long-range goal to serve more than 1 million patients annually by 2028.

Electronic Health Record (EHR) integration, including EPIC, for streamlined ordering

The company is focused on transforming its digital ecosystem, which includes efforts to enhance integration capabilities. While specific adoption numbers for NeoGenomics, Inc. integrations aren't detailed, industry context shows that it may take 4 to 6 months for an IT team to implement a point-to-point integration with a single reference lab. A 2022 report noted a Maryland cancer institute planned to integrate MEDITECH's Expanse Genomics with several labs, including NeoGenomics. Industry-wide, approximately 85% of EHRs offer seamless integration with laboratory systems for real-time result access.

Digital platforms for test ordering and results reporting

The digital infrastructure supports ordering and reporting, with sales teams relying on the integrated LIMS and CRM. The clinical business performance in Q3 2025 showed strong utilization of advanced digital testing platforms, as Next-Generation Sequencing (NGS) testing grew 24% year-over-year and accounted for nearly one-third of clinical revenue. The average revenue per clinical test in the third quarter of 2025 reached $476. The clinical revenue growth for Q3 2025 was 18% compared to Q3 2024.

Here's a quick look at the key performance metrics relevant to channel output for the third quarter of 2025:

Metric	Value (Q3 2025)	Comparison/Context
Consolidated Revenue	$188 million	Up 12% year-over-year
Clinical Revenue Growth (YOY)	18%	Driven by test volumes
Average Revenue per Clinical Test	$476	Up 3% year-over-year
NGS Revenue Share of Clinical Revenue	Nearly one-third	NGS grew 24% year-over-year
Total Employees	2,200	As of September 30, 2025

Finance: review Q4 2025 sales pipeline conversion rates by region by next Tuesday.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Customer Segments

You're looking at how NeoGenomics, Inc. structures its client base, which is really about where the testing dollars are coming from. As of late 2025, the focus is clearly on the clinical side, especially the community setting, even with headwinds in the pharma sector.

The clinical business is the engine. For the third quarter of 2025, total revenue hit a record of \$188 million, with the clinical business driving an 18% year-over-year growth. This segment is where you find the community practices, hospitals, and academic centers.

The company specifically notes its focus on the community setting, stating that approximately 80% of cancer care is delivered there. This tells you where the sales force and service improvements are directed.

The pharmaceutical and biotech firms fall under the non-clinical revenue bucket, and that area has seen pressure. For instance, in the first quarter of 2025, non-clinical revenue declined by 15.8% year-over-year, which the company anticipated.

Here is a breakdown mapping the required segments to the available financial context from the recent quarters:

Customer Segment Group	Primary Revenue Type Context	Key Metric/Data Point (Latest Available)
Community-based pathology and oncology practices	Clinical Revenue	~80% of cancer care delivered in this setting.
Hospital systems and academic medical centers	Clinical Revenue	Part of the clinical business driving 18% YoY growth in Q3 2025.
Pharmaceutical and biotech firms for clinical trials and research	Non-Clinical Revenue	Declined by 15.8% year-over-year in Q1 2025.
Reference laboratories (send-out testing)	Clinical Revenue	Contributes to overall clinical volume, with Average Revenue Per Test at \$476 in Q3 2025.

Within the clinical revenue stream, Next-Generation Sequencing (NGS) is a key value driver for these customers. In the third quarter of 2025, NGS revenue grew by 24% year-over-year and now accounts for nearly one-third of the total clinical revenue.

You can see the overall revenue mix shift by looking at the Q2 2025 figures, where Clinical Revenue was approximately \$160 million out of total revenue of \$181 million, showing the heavy weighting toward direct patient/provider testing.

The average revenue per clinical test (ARPCT) is a good proxy for the value captured from these segments. For the third quarter of 2025, the ARPCT was \$476, up 3% year-over-year.

The company is actively managing its customer base by focusing on high-value tests and maintaining strong relationships in the community. They are positioning themselves as the partner of choice for clinicians.

• NGS testing now represents nearly one-third of clinical revenue.
• The revised full-year 2025 revenue guidance is between \$720 million and \$726 million.
• Q3 2025 total revenue was \$188 million.
• The company is growing its sales team to strengthen the community channel.

If onboarding for new hospital systems takes longer than expected, it definitely impacts the near-term realization of that segment's potential.

Finance: draft 13-week cash view by Friday.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Cost Structure

You're looking at the hard numbers that drive NeoGenomics, Inc.'s operations as of late 2025. It's a cost-intensive business, built on specialized science and infrastructure.

High compensation and benefit costs for specialized staff represent a major component of the overall spend. For instance, in the third quarter of 2025, the increase in operating expenses included approximately $4.7 million attributed to higher compensation and benefit costs, largely driven by the expansion of the commercial sales team. This reflects the need to staff highly skilled personnel across lab operations and sales.

The commitment to staying ahead in oncology diagnostics means significant R&D investment in new product defintely development is a constant drain on cash flow. Looking at the first nine months of 2025, Research and Development expenses totaled $27,898 thousand, up from $23,190 thousand for the same period in 2024. This investment fuels the development of next-generation MRD products and therapy selection tests.

Total Operating expenses are substantial, reflecting the scale of the laboratory network. For the third quarter of 2025, total operating expenses were reported at $107 million, which was an increase of $11 million, or 12%, compared to the third quarter of 2024. This figure includes non-recurring charges, such as $7.1 million in impairment charges related to the planned sale of Trapelo during Q3 2025.

The core of the cost structure lies in the Costs of supplies and reagents for complex testing. This is captured within the Cost of Revenue. For the three months ended September 30, 2025, the Cost of Revenue was $107,351 thousand. This increase, partially offsetting revenue gains, led to a consolidated gross profit margin of 43% for the quarter, though the Adjusted Gross Profit Margin was 45%.

You also have to account for Acquisition and integration costs as NeoGenomics, Inc. continues to expand its footprint. The acquisition of Pathline, LLC, completed in April 2025, involved an initial cash consideration of $8.0 million, subject to adjustments, plus a contingent consideration of $1.0 million. The company anticipates operational consolidation and synergies from this deal will yield substantial annual cost reductions, expected to be accretive to Adjusted EBITDA starting in 2026.

Here's a quick look at the major expense categories for the three months ended September 30, 2025, compared to the prior year period, in thousands of USD:

Expense Category	3 Months Ended Sep. 30, 2025 (in thousands)	3 Months Ended Sep. 30, 2024 (in thousands)
Cost of Revenue	$107,351	$92,944
General and administrative	$69,874	$66,969
Sales and marketing	$21,806	$20,415
Impairment charges (Note 5)	$7,086	$0
Total Operating Expenses	$107,460	$96,077

The breakdown of operating expenses for the third quarter of 2025 shows where the cash is going:

• General and administrative expenses: $69,874 thousand.
• Sales and marketing expenses: $21,806 thousand.
• Research and development expenses: $8,694 thousand.
• Impairment charges: $7,086 thousand.

The company ended the quarter with $164 million in cash and cash equivalents and marketable securities.

Finance: draft 13-week cash view by Friday.

NeoGenomics, Inc. (NEO) - Canvas Business Model: Revenue Streams

You're looking at how NeoGenomics, Inc. brings in its money as of late 2025. It's primarily a testing and services company focused on oncology.

The company's revenue streams are built around its laboratory services, which are segmented by the type of client and test complexity. You'll see the core business is heavily reliant on clinical volume and pricing power.

For the full year 2025, NeoGenomics, Inc. has provided guidance expecting total revenue in the range of $720 million to $726 million. Furthermore, the company guided for Full-year 2025 Adjusted EBITDA guidance of $41 million to $44 million.

Clinical Services Revenue from Diagnostic Testing (Primary Driver)

This is the bread and butter for NeoGenomics, Inc. It covers the testing ordered by oncologists and pathologists to help diagnose and manage cancer treatment for patients. Strength here drives the overall top line, as seen in recent quarters.

For instance, in the third quarter of 2025, total clinical revenue grew by 18% year-over-year. This growth was fueled by a 15% increase in clinical test volumes and a 3% increase in the average revenue per clinical test, which reached $476. That average price increase reflects a mix shift toward more complex, higher-value tests.

The key components driving this segment include:

• Clinical cancer testing services.
• Interpretation and consultative services.
• Validation laboratory services.

Next-Generation Sequencing (NGS) Testing Revenue (High-Growth Segment)

Next-Generation Sequencing (NGS) is a critical, high-growth component within the broader clinical testing category. These are more advanced, comprehensive genomic tests that provide deeper insights for targeted therapy selection.

NGS has been a standout performer. In the third quarter of 2025, NGS revenue specifically grew by 24% year-over-year. This segment benefits from the overall increase in the average revenue per test because NGS tests carry a higher price point than standard tests.

The table below summarizes some recent quarterly performance metrics that feed into this revenue stream:

Metric	Q3 2025 Value	YoY Growth (Q3 2025 vs Q3 2024)
Total Consolidated Revenue	$188 million	12%
Clinical Revenue Growth	Not explicitly stated	15% increase in clinical test volumes
NGS Revenue Growth	Not explicitly stated	24%
Average Revenue Per Clinical Test	$476	3%

Non-Clinical Revenue from Pharmaceutical and Biotech Research Services

This stream comes from providing testing and lab services to pharmaceutical and biotech companies, often supporting their clinical trials or research and development efforts. This revenue can be more lumpy and less predictable than the core clinical business.

You need to watch this segment closely, as it has shown recent weakness. In the third quarter of 2025, non-clinical revenue declined by 27% versus the prior year, which partially offset the strong performance in the clinical segment. This pressure in pharma revenue was cited as a reason for earlier guidance revisions.

The services falling under this category are:

• Clinical trials and research support.
• Comprehensive technical and professional services offering.
• Oncology data solutions.

It's a smaller piece of the pie right now, but it's important for strategic partnerships.